MedTrace Logo

Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis

NCT01342250 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-10-14

No results posted yet for this study

Summary

Although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application. Bone marrow derived mesenchymal stem cells (BM-MSCs) have been shown to replace hepatocytes in injured liver, effectively rescued experimental liver failure and contributed to liver regeneration, which suggest the novel and promising therapeutic strategy In this study, the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation for patients with decompensated liver cirrhosis will be evaluated.

Conditions

Interventions

BIOLOGICAL

conventional therapy plus low dose hUC-MSCs treatment

patients will receive the conventional therapy plus low dose hUC-MSCs treatment

BIOLOGICAL

conventional therapy plus medium dose hUC-MSCs treatment

patients will receive conventional therapy plus medium dose hUC-MSCs treatment

BIOLOGICAL

conventional therapy plus high dose hUC-MSCs treatment

patients will receive conventional therapy plus high dose hUC-MSCs treatment

Sponsors & Collaborators

  • No.85 Hospital, Changning, Shanghai, China

    collaborator OTHER

  • Shenzhen Beike Bio-Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chengwei Chen · No.85 Hospital, Changning, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-07-31
Completion
2011-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342250 on ClinicalTrials.gov